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Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 in Saudi
Arabia and has caused over 2400 cases and more than 800 deaths. Epidemiological
studies identified diabetes as the primary comorbidity associated with severe or lethal
MERS-CoV infection. Understanding how diabetes affects MERS is important because of
the global burden of diabetes and pandemic potential of MERS-CoV. We used a model in
which mice were made susceptible to MERS-CoV by expressing human DPP4, and type 2
diabetes was induced by administering a high-fat diet. Upon infection with MERS-CoV,
diabetic mice had a prolonged phase of severe disease and delayed recovery that was
independent of virus titers. Histological analysis revealed that diabetic mice had delayed
inflammation, which was then prolonged through 21 days after infection. Diabetic mice had
fewer inflammatory monocyte/macrophages and CD4+ T cells, which correlated with lower
levels of Ccl2 and Cxcl10 expression. Diabetic mice also had lower levels of Tnfa, Il6, Il12b,
and Arg1 expression and higher levels of Il17a expression. These data suggest that the
increased disease severity observed in individuals with MERS and comorbid type 2
diabetes is likely due to a dysregulated immune response, which results in more severe and
prolonged lung pathology.
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Introduction
Middle East respiratory syndrome coronavirus (MERS-CoV) was first identified in 2012 in Saudi Arabia 
(1). Since 2012, more than 2400 laboratory-confirmed cases of  MERS-CoV have been identified resulting 
in more than 800 deaths and a case fatality rate of  approximately 35% (2). The vast majority of  MERS-
CoV cases have occurred in Saudi Arabia; however, travel-associated cases have been identified in 27 addi-
tional countries. The most remarkable travel-associated case of  MERS-CoV occurred in 2015 in South 
Korea and caused an outbreak that infected 186 individuals, resulting in 36 deaths (3). Dromedary camels 
(Camelus dromedarius) are thought to be the zoonotic reservoir for MERS-CoV and transmit the virus to 
humans via direct contact with camels or camel products (4–6). Human-to-human transmission appears 
to require close contact and can occur within households, but nosocomial transmission is more common 
and accounts for almost 40% of  all MERS cases (7). The clinical presentation of  MERS-CoV infection can 
range from asymptomatic infections to mild infections that present as a sore throat, fever, and myalgia to 
severe disease that can progress to pneumonia, acute respiratory distress syndrome, and multiorgan failure 
leading to death (8, 9). There is limited information on the pathogenesis of  MERS-CoV in humans, and 
only 2 autopsies have been published (10, 11). These studies showed similar lung pathology, with diffuse 
alveolar damage being the most prominent pathological feature along with hyaline membrane formation, 
edema, and a mixed inflammatory infiltrate (10, 11).
Although there is little known about the mechanisms of  pathogenesis of  MERS-CoV in humans, sev-
eral epidemiological studies have looked at a variety of  aspects of  MERS-CoV infection, including trans-
mission, indicators of  clinical outcome, and risk factors that contribute to the development of  severe or 
lethal disease (7, 12–20). Risk factors that are associated with the development of  more severe disease or 
death following MERS-CoV infection include male sex, older age, and comorbid illnesses (7, 12–15). In 
particular, diabetes, kidney disease, heart disease, underlying respiratory disease, and hypertension have 
all been shown to predispose a patient to more severe or lethal disease after MERS-CoV infection (16–20), 
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how diabetes affects MERS is important because of the global burden of diabetes and pandemic 
potential of MERS-CoV. We used a model in which mice were made susceptible to MERS-CoV by 
expressing human DPP4, and type 2 diabetes was induced by administering a high-fat diet. Upon 
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recovery that was independent of virus titers. Histological analysis revealed that diabetic mice 
had delayed inflammation, which was then prolonged through 21 days after infection. Diabetic 
mice had fewer inflammatory monocyte/macrophages and CD4+ T cells, which correlated with 
lower levels of Ccl2 and Cxcl10 expression. Diabetic mice also had lower levels of Tnfa, Il6, Il12b, 
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disease severity observed in individuals with MERS and comorbid type 2 diabetes is likely due to a 
dysregulated immune response, which results in more severe and prolonged lung pathology.
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and having more than 1 comorbid illness further increases the risk for severe disease (17). Furthermore, 
asymptomatic individuals were less likely to have an underlying comorbidity compared with those with 
fatal cases (21). In a transmission study within a single extended family, members who tested positive for 
MERS-CoV were over 3 times as likely to have a comorbid disease (22). One study found that 15/17 (88%) 
individuals who had diabetes had a poor disease outcome characterized by intensive care unit admission 
or death compared with 7/18 (39%) individuals who had any type of  nondiabetic comorbidity, which sug-
gests that diabetes in particular is a major contributor to MERS-CoV disease severity (23). Although there 
is a large amount of  heterogeneity in the level of  risk associated with the various comorbidities because of  
study designs and target populations, the reports demonstrate that diabetes is a significant risk factor for the 
development of  severe or lethal disease from MERS-CoV infection. The odds ratio of  developing severe or 
lethal disease following MERS-CoV infection when one has comorbid diabetes ranges from 2.47 to 7.24, 
depending on the study design and population (16–20, 22). Interestingly, diabetes has also been shown to be 
a risk factor for other lower respiratory tract infections, including Mycobacterium tuberculosis (M. tuberculosis), 
Burkholderia pseudomallei (B. pseudomallei), and influenza virus (24).
More than 425 million people across the globe have diabetes, which can be further classified into type 1 
diabetes (T1D) and type 2 diabetes (T2D) (25). Both T1D and T2D result in hyperglycemia, but the mech-
anism by which this occurs is different. T1D typically results from an autoimmune-like disease in which β 
cells in the pancreas are destroyed, resulting in decreased insulin production. T2D, however, results from 
the body’s inability to respond properly to insulin. T2D is the most prevalent form of  diabetes, constituting 
more than 85%–95% of  all diabetes cases (25). The etiology of  T2D is closely intertwined with obesity and 
results from chronic inflammation induced by excess adipose tissue. Stressed adipocytes and adipose tissue 
macrophages secrete numerous proinflammatory mediators that result in chronic low-grade inflammation, 
which alters homeostatic glucose regulation by decreasing cellular responsiveness to insulin (26, 27). This 
results in key physiological characteristics of  T2D: hyperglycemia, hyperinsulinemia, and glucose intoler-
ance. Humans and mice with T2D exhibit a switch from predominately regulatory or antiinflammatory 
macrophages and regulatory T cells (Tregs) in adipose tissue to predominately proinflammatory macro-
phages and Th1 and Th17 CD4+ T cells (28, 29). This altered immune profile is thought to contribute to a 
variety of  the consequences associated with T2D, including increased susceptibility to infection (30).
Recently, small animal models suitable for studying MERS-CoV infection have been created, and 
mechanisms of  pathogenesis are now able to be studied. MERS-CoV does not replicate in wild-type mice 
because of  differences in the receptor binding domain of  DPP4 (31–33). To overcome this, many groups, 
including ours, have developed transgenic mice that express human DPP4 (34–39). In our model, exons 
2–25 of  mouse DPP4 were replaced with the human DPP4 sequence (DPP4H/M) (34). These mice express 
human DPP4 in the appropriate cell types, including nonciliated epithelial cells and alveolar type 2 cells, 
and support MERS-CoV replication in the lung. Following infection with MERS-CoV (Jordan), mice lose 
weight; show clinical signs of  illness, including labored breathing and lethargy; and exhibit pulmonary 
histopathological characteristics similar to those observed in humans (34, 35). Furthermore, we observed 
immune cell infiltration primarily characterized by monocyte/macrophages and T cells as well as increased 
expression of  proinflammatory cytokines and chemokines. Immune cell depletion studies have shown that 
CD8+ T cells may play a role in promoting tissue damage whereas macrophages may play a role in pro-
tection (35). Other humanized mouse models for studying MERS-CoV pathogenesis have also shown a 
critical role for inflammatory macrophages and monocytes (IMMs) as well as T cells in coordinating an 
appropriate immune response following MERS-CoV infection (36).
Understanding how diabetes contributes to disease severity following MERS-CoV infection and how to 
treat infection in this context is critical. Ongoing transmission of  MERS-CoV continues in Saudi Arabia, 
a country that also has a high prevalence of  T2D (approximately 18%) (25). In addition, MERS-CoV is 
a high-consequence respiratory pathogen with pandemic potential, which, along with the global burden 
of  diabetes, highlights the need to understand the role of  diabetes during MERS-CoV pathogenesis. We 
successfully developed a small animal model that is susceptible to MERS-CoV infection and develops T2D 
to mimic the human condition to study the effect of  comorbid diabetes on MERS-CoV pathogenesis. Male 
DPP4H/M mice fed a high-fat diet (HFD) for 12 to 17 weeks develop hyperglycemia, hyperinsulinemia, 
and glucose intolerance, which are characteristics of  human T2D. Following infection with MERS-CoV, 
diabetic DPP4H/M mice exhibit more severe disease characterized by a prolonged period of  weight loss and 
clinical disease. Exacerbated and prolonged disease in diabetic DPP4H/M mice does not appear to be due to 
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increased virus replication or slower virus clearance in the lungs; however, diabetic mice do exhibit a dys-
regulated immune response after infection. Histological and flow cytometric analysis of  the lungs revealed 
that diabetic mice have a delay in the initiation of  inflammation in the lung exemplified by reduced CD4+ 
T cell and IMM recruitment and are slower to resolve lung inflammation compared with control mice. In 
addition, we observed delayed and dampened chemokine expression in diabetic mice along with altered 
cytokine profiles. This model demonstrates that comorbid diabetes in an HFD model resulted in a dysreg-
ulated immune response to MERS-CoV infection, which will help elucidate mechanisms of  pathogenesis 
that may be occurring in humans with diabetes and provides a model for studying therapeutics for this 
highly susceptible population.
Results
Male DPP4H/M mice develop diet-induced T2D and exhibit prolonged severe disease following MERS-CoV infection. 
Diabetes is a significant risk factor for the development of  severe or lethal disease following MERS-CoV 
infection in humans (16–20, 22). We sought to determine how diabetes predisposes humans to increased 
morbidity and mortality after MERS-CoV infection by creating a T2D small animal model that is permissive 
to MERS-CoV infection. We previously characterized a mouse model that showed significant pathology fol-
lowing MERS-CoV infection when exons 2–25 of  mouse DPP4 were replaced with human DPP4 sequence 
(DPP4H/H) in mice on a C57BL/6 background (34, 35). Importantly, C57BL/6 mice are susceptible to the 
development of  obesity and T2D after being fed an HFD for an extended period (40, 41). Although we 
have not observed any physiological or immunological differences between DPP4H/H and wild-type mice, 
we chose to use mice that were heterozygotes for the human DPP4 allele (DPP4H/M) to avoid any unknown 
species-specific complications. To induce T2D, male and female mice were fed either a normal diet or an 
HFD beginning at 4 to 6 weeks of  age and maintained on the specified diet for 12 to 17 weeks. Mice were 
then evaluated for the development of  metabolic disease. Studies focused on animal models for obesity and 
diabetes have found sex-specific differences in C57BL/6 mice in which males were more susceptible to both 
obesity and T2D (40). For these reasons, experimental groups were stratified by diet and by sex.
Male and female mice maintained on an HFD for 12 to 17 weeks weighed significantly more than their 
control counterparts (Figure 1A, P < 0.0001), and males fed an HFD gained significantly more weight than 
HFD females (Figure 1A, P < 0.0001). To determine whether HFD DPP4H/M mice developed characteristics 
of T2D, we performed metabolic testing to evaluate hyperglycemia, hyperinsulinemia, and glucose tolerance. 
Hyperglycemia was determined by fasting mice for 16 hours, after which blood glucose levels were determined. 
HFD male and female DPP4H/M mice had significantly higher concentrations of glucose in the blood compared 
with control mice (Figure 1B, P < 0.0001), and HFD male mice had significantly higher levels of glucose in the 
blood compared with HFD females (Figure 1B , P < 0.0001). Fasted serum insulin levels were determined by 
ELISA to evaluate the development of hyperinsulinemia in HFD DPP4H/M mice. HFD male mice had signifi-
cantly higher levels of serum insulin compared with control males whereas HFD females had similar levels of  
serum insulin as control mice (Figure 1C, P < 0.05). Finally, we evaluated glucose tolerance in HFD DPP4H/M 
mice using an intraperitoneal glucose tolerance test (IPGTT), which measures how quickly a bolus of glucose is 
controlled. A healthy mouse can control blood glucose levels within 2 hours of glucose administration where-
as glucose levels remain elevated in mice with glucose intolerance and reduced insulin function. As expected, 
control male and female mice exhibited glucose tolerance where blood glucose levels peaked 30 minutes after 
administration and were reduced to baseline levels by 2 hours after administration; however, HFD male (Figure 
1D, P < 0.0001) and female mice (Figure 1E, P < 0.0001) exhibited significant glucose intolerance. Glucose tol-
erance can also be assessed by determining the area under the curve (AUC) of the IPGTT measurements during 
the time course. The AUC of the IPGTT of HFD male and female DPP4H/M mice was significantly greater than 
control mice (Figure 1F, P < 0.0001), and male HFD mice had a greater AUC of the IPGTT than female HFD 
mice (Figure 1F, P < 0.0001). Together, these data show that male DPP4H/M mice fed an HFD developed met-
abolic disease consistent with T2D in humans, characterized by hyperglycemia, hyperinsulinemia, and glucose 
intolerance, whereas female DPP4H/M mice fed an HFD developed less severe metabolic disease, characterized 
by mild hyperglycemia and glucose intolerance, but not hyperinsulinemia. We continued to use HFD male 
DPP4H/M (diabetic) mice and HFD female DPP4H/M (HFD) mice for the remainder of these studies to deter-
mine whether the extent of T2D affects MERS-CoV pathogenesis. For the remainder of this paper, HFD male 
mice will be referred to as “diabetic” and HFD female mice will be referred to as “HFD” because they developed 
mild metabolic syndrome associated with obesity that does not meet the criteria of T2D.
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Next, we wanted to determine whether having diabetes affects the clinical course of disease. Diabetic male 
and HFD female mice along with control male and female mice were intranasally infected with 1.5 × 105 PFU 
of MERS-CoV Jordan and evaluated daily for weight loss and the appearance of clinical signs of disease. Male 
diabetic mice lost a similar percentage of their initial body weight as control mice during infection; however, 
diabetic mice were slower to add on weight (Figure 2A, P = 0.0439). Because of the weight difference between 
diabetic and control mice, we also looked at the changes of absolute mass lost and found that diabetic mice 
continued to lose weight for a longer period than control mice and lost significantly more net mass following 
MERS-CoV infection (Figure 2C, P < 0.0001). Diabetic male mice also exhibited prolonged severe clinical signs 
of disease that persisted through 21 days after infection, with labored breathing being the most notable feature 
that persisted in diabetic male mice (Figure 2E, P < 0.0001). The clinical course of disease was more similar 
between female HFD and control mice with less of a difference in the extent of weight lost (Figure 2, B and D). 
However, elevated clinical scores were observed through 21 days after infection in HFD female mice compared 
with normal female mice (Figure 2F). Lethal disease in this model is defined as either found dead in the cage 
or reaching 30% weight loss. We did not observe any significant differences in mortality between diabetic and 
control male mice or HFD and control female mice (Supplemental Table 1; supplemental material available 
online with this article; https://doi.org/10.1172/jci.insight.131774DS1). These data demonstrate the utility of  
this animal for studying how diabetes affects MERS-CoV pathogenesis. These data show that diabetic DPP4H/M 
mice had prolonged severe disease following MERS-CoV infection, as characterized by an extended period of  
weight loss and the persistence of labored breathing through 21 days after infection.
Diabetes does not affect virus replication or clearance in the lung and does not result in extrapulmonary dissemina-
tion of  the virus. To date, no studies have been performed in humans analyzing virus titers in the context of  
comorbid diabetes. We have previously shown in our mouse model that higher levels of  virus replication are 
associated with more severe MERS-CoV infections (34, 35). To determine whether virus replication is altered 
Figure 1. Male DPP4H/M mice develop type 2 diabetes on an HFD. DPP4H/M mice were split into age- and sex-matched cohorts at 4 to 6 weeks of age 
and maintained on either a high-fat chow (diabetic) or normal chow (control) diet. The (A) weight, (B) fasted blood glucose concentration, and (C) 
fasted serum insulin concentrations were determined. Glucose tolerance was determined using an intraperitoneal glucose tolerance test (IPGTT) in 
which 2 mg/kg of glucose was administered intraperitoneally and blood concentrations were measured every 30 minutes for 2 hours. The data for 
(D) male and (E) female mice were normalized to the baseline fasted glucose concentration, and (F) the area under the curve (AUC) was determined. 
Data for A, B, and D–F are pooled from 4 independent experiments with n = 37–53 mice/group presented as the mean ± SEM. ****P < 0.0001 as 
determined by 1-way ANOVA with Tukey’s posttest. Data for C are pooled from 2 independent experiments with n = 13–17 mice/group presented as 
the mean ± SEM. *P = 0.0256 as determined by 1-way ANOVA with Tukey’s posttest.
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in diabetic mice, we infected diabetic and control male and HFD and control female mice with 1.5 × 105 
PFU of MERS-CoV Jordan and euthanized mice at days 2, 4, 7, 10, 14, and 21 for analysis. Lung tissue was 
homogenized in PBS, and infectious virus titers were determined by plaque assay. We observed no differences 
in virus titers between diabetic and control male (Figure 3A) or HFD and control female mice (Figure 3B). 
We also quantified the amount of  MERS-CoV genomic RNA and mRNA in the lungs of  diabetic and control 
mice during infection. We found no differences in the amount of  genomic virus RNA or virus mRNA in the 
lungs of  diabetic and control male (Figure 3, C and E) or HFD and control female mice (Figure 3, D and F). 
Together these data suggest that virus replication and clearance are not affected by diabetes or HFD.
It is not clear how common extrapulmonary dissemination and replication of MERS-CoV are in humans 
because of the minimal amounts of virology data from patients with MERS. One human autopsy case study 
cited the presence of virus antigen in the lungs as well as the spleen whereas the other available autopsy did 
not find any evidence of extrapulmonary virus, and neither of these individuals were reported to have diabetes 
(10, 11). Furthermore, another study found virus in the blood and urine of an individual who had diabetes and 
Figure 2. Diabetic male DPP4H/M mice exhibit prolonged severe disease following high-dose MERS-CoV infection. 
Male diabetic and control and female HFD and control DPP4H/M mice were infected intranasally with 1.5 × 105 PFU of 
MERS-CoV Jordan. The (A and B) percentage of weight loss and (C and D) amount of weight lost were measured daily in 
(A and C) male and (B and D) female mice. Clinical signs of disease were also assessed daily in (E) male and (F) female 
mice. Clinical scores were determined on the following scale: 0 = healthy; 1 = slight ruffling of the fur, altered hind limb 
posture; 2 = mildly labored breathing, no lethargy, 3 = moderately labored breathing, lethargy; 4 = severely labored 
breathing, severe lethargy; and 5 = dead. Data are presented as the mean ± SEM and are pooled from 3 independent 
experiments with n = 12–17 mice/group. *P < 0.0239; **P < 0.01; ***P < 0.001; and ****P < 0.0001 as determined by 
2-way ANOVA with Holm-Šídák posttest.
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succumbed to infection whereas an individual who did not have diabetes survived and only had positive respi-
ratory samples (42). To determine whether diabetes leads to extrapulmonary virus dissemination, we infected 
mice with 1.5 × 105 PFU of MERS-CoV Jordan and collected lung, brain, kidney, liver, spleen, and whole 
blood from diabetic and control male and HFD and control female mice 7 days after infection. RNA was iso-
lated from the tissues, and the levels of genomic virus RNA and virus mRNA were determined by quantitative 
reverse transcription PCR (qRT-PCR). Again, we found no differences in the amount of genomic virus RNA 
or virus mRNA in the lungs of diabetic and control male mice (Figure 3, G and I); however, HFD female 
mice had lower levels of virus genomic RNA and mRNA compared with control mice 7 days after infection 
(Figure 3, H and J). MERS-CoV genomic RNA was detected in the blood and to a lesser degree in the liver and 
spleen of diabetic and control mice, as well as HFD and control female mice; however, the levels detected were 
much lower than what we observed in the lung (Figure 3, G–J). MERS-CoV mRNA, a marker of active virus 
replication, was detected only in the lung and to a lesser degree in the blood of all mice (Figure 3, I and J). No 
differences in the amount of genomic virus RNA or virus mRNA were observed in any of the extrapulmonary 
tissues or blood isolated from diabetic male and control mice or HFD and control female mice (Figure 3, G–J). 
These data suggest that prolonged disease following MERS-CoV infection is not due to increased virus replica-
tion, a delay in virus clearance, or increased extrapulmonary dissemination of the virus.
Figure 3. Diabetes does not alter virus replication and clearance within the lung or extrapulmonary virus dissemination. Male diabetic and control and 
female HFD and control DPP4H/M were infected intranasally with 1.5 × 105 PFU of MERS-CoV Jordan. (A and D) Lungs were collected at days 2, 4, 7, 10, and 
14 after infection from male (A) and female (D) mice and homogenized in PBS. Lung titers were determined by plaque assay. Data are pooled from 2 to 
3 independent experiments with n = 3–8 mice/group. Data are presented as the mean ± SEM. No data were determined to be significant using a 2-way 
ANOVA with Holm-Šídák posttest. (B, C, E, and F) Lungs were collected at days 2, 4, 7, 10, 14, and 21 after infection and homogenized in TRIzol. RNA was 
isolated and levels of viral genomic RNA (B and E) and viral mRNA (C and F) were determined using qRT-PCR targeting UpE and M, respectively. Data were 
normalized to transferrin receptor protein 1 (TfRC) and then normalized to PBS controls and are presented as relative units. Data are pooled from 2 to 3 
independent experiments with n = 3–11 mice/group and are presented as the mean ± SEM. (G–J) Lung, whole blood, brain, liver, kidney, and spleen from 
infected male (G and I) and female (H and J) mice 7 days after infection. Virus genomic RNA (G and H) and virus mRNA (I and J) were determined using 
qRT-PCR targeting UpE and M, respectively. Data were normalized to TfRC and then normalized to PBS controls and are presented as relative units. Data 
are from n = 4–11 mice/group and are presented as the mean ± SEM.
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Inflammation in the lungs of  diabetic male mice is delayed but prolonged following MERS-CoV infection. Weight 
loss and the appearance of  clinical signs of  disease are typically associated with lung pathology. To better 
understand the kinetics of  lung inflammation and pathology following MERS-CoV infection in diabetic 
mice, we infected mice with 1.5 × 105 PFU of  MERS-CoV Jordan and collected lung tissue at days 2, 4, 
7, 10, 14, and 21 after infection. The lung tissue was stained with hematoxylin and eosin for histological 
examination in which slides were blinded and were scored by a board-certified pathologist for inflamma-
tion and lung pathology (Tables 1 and 2). Control male (Figure 4) and female (Supplemental Figure 1) 
mice had a moderate degree of  lung inflammation 2 days after infection, which was predominately located 
around vasculature with limited bronchiolar inflammation. In contrast, male diabetic mice (Figure 4D) and 
female HFD mice (Supplemental Figure 1D) had significantly less perivascular inflammation compared 
with control mice 2 days after infection. Around 4 to 7 days after MERS-CoV infection, lung pathology 
was similar between diabetic and control male mice and HFD and control female mice and was character-
ized by increasing bronchiolar and perivascular inflammation composed primarily of  a mixed macrophage 
Table 1. Histological summary of lung pathology from male DPP4H/M mice infected with 1.5 × 105 PFU of MERS-CoV Jordan
2 dpi 4 dpi 7 dpi 10 dpi 14 dpi 21 dpi
Pathology metric Ctrl Db Ctrl Db Ctrl Db Ctrl Db Ctrl Db Ctrl Db
Overall inflammation ++ + ++ ++ +++ +++ +++ +++ ++++ +++ ++ ++++
Bronchiolar inflammation + – + + ++ +++ +++ +++ ++ ++ + +++
Perivascular/arterial 
inflammation
++ + ++ ++ ++ +++ +++ +++ ++ ++ ++ +++
Pleuritis – – + – + + + + ++ ++ + ++
Edema – – – – ++ ++ ++ +++ ++ + – +
Hemorrhage + + + + + + ++ + – + + –
Eosinophils – – – – – – – – – – – –
Neutrophils + – + – + + – – – – – –
Macrophages + – + + +++ ++ ++++ +++ ++++ +++ ++ +++
Lymphocytes ++ + ++ ++ +++ +++ +++ +++ ++ ++ ++ +++
Interstitial/alveolar 
necrosis
– – – – + – – – – – – –
Bronchiolar necrosis – – – – – – – – – – – –
Average score of n = 5–11 mice/group. –, no inflammation; +, scant inflammation (<5%); ++, mild inflammation (5%–25% parenchyma); +++, moderate 
inflammation (25–50% parenchyma); ++++, marked inflammation (50%–75% parenchyma); +++++, severe infalmmation (>75% parenchyma); Ctrl, control; 
Db, diabetic; dpi, days after infection.
 
Table 2. Histological summary of lung pathology from female DPP4H/M mice infected with 1.5 × 105 PFU of MERS-CoV Jordan
2 dpi 4 dpi 7 dpi 10 dpi 14 dpi 21 dpi
Pathology metric Ctrl HFD Ctrl HFD Ctrl HFD Ctrl HFD Ctrl HFD Ctrl HFD
Overall inflammation +++ + +++ ++ +++ +++ ++++ +++ ++++ +++ +++ ++
Bronchiolar inflammation + + ++ ++ ++ ++ +++ +++ +++ ++ ++ +
Perivascular/arterial inflammation +++ + +++ ++ +++ +++ +++ ++ +++ +++ +++ ++
Pleuritis + – + + + ++ + + + + + +
Edema – – + + ++ ++ +++ +++ ++ + – –
Hemorrhage + – + + + + ++ + + – – –
Eosinophils – – + – + – – – – – – –
Neutrophils – – + + + + – – – – – –
Macrophages + – ++ + +++ +++ ++++ +++ ++++ +++ +++ ++
Lymphocytes +++ + +++ ++ +++ +++ +++ ++ +++ +++ +++ ++
Interstitial/alveolar necrosis – – + – + – – – – – – –
Bronchiolar necrosis – – – – – – – – – – – –
Average score of n = 5–11 mice/group.
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and lymphocyte infiltrate with few apparent granulocytes. By 21 days after infection, diabetic male mice 
still exhibited significant lung pathology and inflammation compared with control male mice (Figure 4, 
B–D) whereas inflammation in female HFD mice was similar to that observed in control mice (Supplemen-
tal Figure 1, B–D). Edema was evident by 7 days following infection, increased through 10 to 14 days after 
infection, and resolved by 21 days after infection, but no differences were observed between diabetic and 
control male mice or HFD and control female mice (Tables 1 and 2). Minimal amounts of  hemorrhage and 
alveolar, bronchiolar, and interstitial necrosis were observed in diabetic and control male mice or HFD and 
control female mice during infection (Tables 1 and 2). These data suggest that a delayed immune response 
in diabetic mice along with the inability to resolve inflammation and lung pathology contributes to more 
severe disease following MERS-CoV infection.
Diabetic mice have a decreased CD4+ T cell and inflammatory monocyte/macrophage response following MERS-CoV 
infection. The pathology data demonstrated that the kinetics and degree of inflammation in the lungs of diabetic 
male mice were altered compared with control mice. To better define the immune response to MERS-CoV 
infection in the context of diabetes, we wanted to determine the kinetics of immune cell infiltration in the 
lungs of diabetic male, HFD female, and control MERS-CoV–infected mice. Single cells were isolated from 
the lung tissue of uninfected or MERS-CoV–infected mice at days 4, 7, 14, and 21 after infection, and flow 
cytometric analysis was performed to identify CD45+ immune cells, CD3+ T cells, CD4+ T cells, CD8+ T cells, 
B cells, NK cells, neutrophils, and IMMs (gating scheme, Supplemental Figure 2). A summary of the number 
and frequency of immune cell subsets can be found in Supplemental Tables 2 and 3. We found more CD45+ 
cells in the lungs of control male mice (1.9 × 107 cells) compared with diabetic male mice (1.3 × 107 cells) 7 
days after infection (Figure 5A). A similar number of CD8+ T cells (Figure 5E), NK cells (Figure 5G), and 
neutrophils (Figure 5H) were found in the lungs of control male and diabetic male mice during MERS-CoV 
infection. The number of B cells found in the lungs of control mice was consistently, though not significantly, 
Figure 4. Lung histology shows delayed and unresolved inflammation in male diabetic mice infected with MERS-CoV. Male diabetic and control DPP4H/M 
mice were infected intranasally with 1.5 × 105 PFU of MERS-CoV Jordan. (A) Lungs were collected at days 2, 4, 7, 10, 14, and 21 after infection and fixed in 
10% neutral buffered formalin for more than 24 hours. Tissue was embedded in paraffin and 5-μm sections were cut and stained with hematoxylin and 
eosin. Blood vessels are marked by arrowheads, and airways are marked by an asterisk (*). Images are shown at original magnification ×10 and are repre-
sentative of n = 5–11 mice/group from 2 to 3 independent experiments. (B) Overall lung inflammation, (C) bronchiolar inflammation, and (D) perivascular 
inflammation were scored by a board-certified veterinarian. The data are pooled from 2 to 3 independent experiments with n = 5–11 mice/group. Data are 
presented as the mean ± SEM. *P < 0.05; ***P < 0.001; and ****P < 0.0001 as determined by 2-way ANOVA with Holm-Šídák posttest.
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higher during infection (Figure 5F), and the frequency of B cells was significantly lower at 14 and 21 days after 
infection during infection (Supplemental Table 2). Diabetic male mice had fewer CD4+ T cells at days 4 and 7 
after infection compared with control male mice, although these data did not reach statistical significance when 
accounting for multiple comparisons (4 dpi: 5.5 × 105 vs. 1.1 × 106 cells; 7 dpi: 1.1 × 106 vs. 2.3 × 106 cells) 
(Figure 5D); however, the frequency of CD4+ T cells was lower at 4 and 7 days after infection (Supplemental 
Table 2). We also found that male diabetic mice had significantly fewer IMMs in the lungs 7 days after infection 
compared with control male mice (6.7 × 105 vs. 1.3 × 106 cells, P = 0.0122; Figure 5B). Female HFD mice had 
significantly fewer neutrophils 7 days after infection (Supplemental Figure 3H), with no differences in the total 
number of CD45+ cells or other immune cell subsets during infection (Supplemental Figure 3). These data 
suggest that the immune response to MERS-CoV infection is dysregulated in diabetic mice with fewer IMMs 
and CD4+ T cells being recruited to the lung.
Cytokine and chemokine gene expression is altered in male diabetic DPP4H/M mice during MERS-CoV infection. 
Immune cell infiltration is coordinated and shaped by the induction of  chemokines and cytokines from 
Figure 5. Diabetic male mice have fewer CD4+ T cells and inflammatory monocyte/macrophages in the lungs at 
peak inflammation following MERS-CoV infection. Male diabetic and DPP4H/M mice were infected intranasally 
with 1.5 × 105 PFU of MERS-CoV Jordan. Lungs were collected at days 4, 7, 14, and 21 after infection or from unin-
fected mice, and single cells were isolated from the tissue. Flow cytometric analysis was performed on the cells 
isolated from the lung. The numbers of (A) CD45+ cells, (B) inflammatory monocyte/macrophages, (C) CD3+ T cells, 
(D) CD4+ T cells, (E) CD8+ T cells, (F) B cells, (G) NK cells, and (H) neutrophils were determined. The data are pooled 
from 2 independent experiments with n = 3–9 mice/group. Data are presented as the mean ± SEM. *P < 0.05 as 
determined by 2-way ANOVA with Holm-Šídák posttest.
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infected and neighboring cells. We found that cellular infiltration was altered in diabetic male mice, but 
not HFD female mice, during MERS-CoV infection and hypothesized that there may be alterations in 
chemokines responsible for cellular recruitment in diabetic male mice. To investigate this, we performed 
gene expression analysis using qRT-PCR on RNA isolated from the lungs of  male diabetic and control 
mice as well as female HFD and control mice infected with MERS-CoV at days 2, 4, 7, 10, 14, and 21 
after infection. We first focused on Ccl2 and Cxcl10, which drive monocyte and lymphocyte recruitment, 
respectively, because they have been previously shown to be upregulated during MERS-CoV infection in 
our mouse model (35). We found that diabetic male mice had significantly reduced levels of  Ccl2 expres-
sion at days 2 (P = 0.0084) and 7 (P = 0.0014) after infection (Figure 6A). We also found that diabetic 
Figure 6. Cytokine and chemokine gene expression in the lungs is altered in male diabetic DPP4H/M mice following MERS-CoV infection. Male diabetic 
and control DPP4H/M mice were infected intranasally with 1.5e5 PFU of MERS-CoV Jordan. Lung tissue was collected at days 2, 4, 7, 10, 14, and 21 after 
infection and from PBS-infected mice and was homogenized in TRIzol. RNA was isolated, cDNA was synthesized, and gene expression was determined 
using quantitative PCR. Gene expression was normalized to GAPDH, and fold change was calculated relative to PBS infected mice. Gene expression was 
determined for (A) Ccl2, (B) Tnfa, (C) Il6, (D) Il12b, (E) Nos2, (F) Arg1, (G) Cxcl10, (H) Il4, (I) Ifng, (J) Il17a, (K) Foxp3, and (L) Il10. Data are pooled from 2 to 3 
independent experiments with n = 3–16 mice/group and are presented as the mean ± SEM. *P < 0.05; **P < 0.01; and ***P < 0.001 as determined by 2-way 
ANOVA with Holm-Šídák posttest.
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male mice had significantly lower levels of  Cxcl10 expression 2 days after infection (P = 0.0011). Ccl2 
expression was similar in female HFD and control mice (Figure 6) while Cxcl10 expression was actually 
higher in HFD female mice 2 days after infection (P = 0.0006, Figure 6G). Significantly less chemokine 
expression early during infection may play a role in the delayed recruitment of  immune cells to the site 
of  infection in male diabetic mice.
Next, we looked at cytokines that CD4+ T cells produce. Our flow cytometry data demonstrated a 
reduction in CD4+ T cells, so we determined whether there were also any changes in cytokines that are 
indicative of  CD4+ T cell function. We focused on Ifng, Il4, Il17a, and the transcription factor Foxp3 to 
evaluate Th1, Th2, Th17, and Treg skewing, respectively. We found very little expression of  Il4 during 
MERS-CoV in male (Figure 6H) and female (Supplemental Figure 4H) mice regardless of  metabolic status. 
Ifng expression peaked 7 days after infection and was similar in male diabetic and control mice (Figure 6I) 
but was significantly lower in female HFD mice (Supplemental Figure 4I, P < 0.0001). Interestingly, we 
observed significantly higher Il17a expression in male diabetic mice beginning at 7 days after infection (P 
= 0.0264), and elevated expression compared with control mice continued through 21 days after infection 
(Figure 6J) whereas female mice had very little upregulation of  Il17a following MERS-CoV infection (Sup-
plemental Figure 4J). We also found that Foxp3 expression was higher 21 days after infection in diabetic 
male (Figure 6K, P = 0.0152) and HFD female (Supplemental Figure 4K, P < 0.0001) mice. These data 
suggest that not only are there fewer CD4+ T cells in the lungs of  diabetic mice, but there may also be a 
difference in the skewing of  these cells with a more prominent Th17 response in diabetic male mice that 
may contribute to disease severity along with a more prominent Treg response 21 days after infection when 
inflammation in control mice is diminishing.
Previous work showed that macrophages play an important role during MERS-CoV pathogenesis 
(35). Furthermore, macrophage skewing has been shown to be important during SARS-CoV pathogene-
sis (43). To evaluate what effects diabetes has on macrophage skewing during MERS-CoV infection, we 
evaluated the gene expression patterns of  the proinflammatory M1-related genes Tnfa, Il6, and Nos2 as 
well as the antiinflammatory M2-related genes Il10 and Arg1. Diabetic male mice had reduced upregula-
tion of  Tnfa at 2 (P = 0.0145) and 7 (P = 0.0041) days after infection (Figure 6B) and reduced upregula-
tion of  Il6 2 days after infection (Figure 6C); however, Nos2 expression was upregulated similarly in the 
lungs of  male diabetic and control mice during MERS-CoV infection (Figure 6E). Il10 expression was 
similar in male diabetic and control mice (Figure 6L), but Arg1 expression had reduced upregulation at 
7 (P = 0.0009) and 10 (P = 0.0332) days after infection in male diabetic mice (Figure 6F). No differences 
in Tnfa, Il6, Nos2, Arg1, or Il10 were found between female HFD and control mice (Supplemental Figure 
4). These data suggest that diabetic mice have reduced chemokine expression, which results in delayed 
immune cell recruitment to the lung during MERS-CoV infection. Furthermore, the CD4+ T cell and 
macrophage responses are not only lower in diabetic mice, but the cytokine profiles associated with these 
cell subsets are also altered. The immune dysregulation observed may be contributing to the more severe 
pathogenesis of  MERS-CoV in diabetic mice.
Discussion
Clinical and epidemiological analyses have identified preexisting comorbidities, including diabetes, as 
important risk factors for the development of  severe or lethal disease following MERS-CoV infection (7, 
12–20, 22). To understand how diabetes is contributing to MERS-CoV pathogenesis, we developed a small 
animal model that is both susceptible to MERS-CoV infection and has T2D induced by an HFD (Fig-
ure 1). Following infection with MERS-CoV, diabetic DPP4H/M mice exhibited more severe clinical symp-
toms characterized by a prolonged period of  weight loss and clinical disease with lung histology revealing 
delayed initiation of  inflammation and slower inflammatory resolution (Figures 2 and 4). Flow cytometric 
analysis showed that the IMM response and, to a lesser extent, the CD4+ T cell response were altered in 
diabetic mice following MERS-CoV infection, with delayed infiltration kinetics, fewer cells at peak inflam-
mation, and reduced chemokine and cytokine induction (Figures 5 and 6).
MERS-CoV does not infect wild-type mice because of  differences in the receptor binding domain of  
the cellular receptor DPP4 (31–33). For this reason, we needed to use mice that are transgenic for human 
DPP4 for productive infection. DPP4 is an aminopeptidase that exists in 2 forms, membrane bound and 
secreted, and plays a role in various physiological processes, including the immune response and glucose 
metabolism (44). DPP4 acts as a costimulatory molecule for T cells and interacts with various proteins, 
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including adenosine deaminase and caveolin-1 (45). The enzymatic activity of  DPP4 results in the cleavage 
of  a variety of  protein targets, including cytokines, chemokines, and growth factors, altering their function 
(45). The enzymatic activity of  DPP4 also targets the incretins glucagon-like peptide-1 and gastric inhibi-
tory peptide and cleaves these molecules, leading to a decrease in insulin secretion (44). Antidiabetic drugs 
known as gliptins target the enzymatic activity of  DPP4 to block this cleavage, thus increasing insulin 
secretion and decreasing blood glucose levels. Gliptins have also been found to alter the immune response 
in mice and humans (45). Of  note, the IC50 for a wide range of  gliptins is similar between mice and humans 
when enzymatic inhibition is tested in vitro (46). We found that DPP4H/M mice developed T2D similarly to 
wild-type C57BL/6 mice when fed an HFD (40, 47). The species cross-reactivity of  gliptins as well as other 
drugs used to treat T2D, including metformin and sulfonylureas, will allow us to study the effects of  anti-
T2D drugs on MERS-CoV pathogenesis. Although we have not found any differences between wild-type 
and humanized DPP4 mice in regard to the immune response and glucose metabolism, it cannot be ruled 
out that DPP4H/M mice have alterations compared with wild-type mice.
Obesity and diabetes have both been identified as significant risk factors for severe disease following lower 
respiratory tract infections. Diabetes, in particular, is associated with worse disease following MERS-CoV, M. 
tuberculosis, and B. pseudomallei infection whereas obesity is more often associated with worse disease following 
influenza infection (24). Both diabetes and obesity result in a dysregulated immune response to respiratory 
infections (30, 48–52), but delineating the effects of excess adipose tissue and dyslipidemia associated with 
obesity compared with the effects of hyperglycemia and excess insulin production associated with T2D on the 
immune response to infection has not been evaluated. Part of the reason for this is that obesity and T2D are 
closely linked, and the etiology of T2D is thought to be due to chronic inflammation that is induced by excess 
adipose tissue and obesity (26, 27). Because of this etiology, the HFD mouse model is used to study obesity as 
well as T2D. Genetic models of obesity in which mice lack the leptin gene (ob/ob) or the leptin receptor (db/db) 
also result in metabolic syndrome and T2D, making it difficult to delineate the contribution of obesity or T2D 
alone (53). Our future studies include creating a lean hyperglycemic mouse model that recapitulates the meta-
bolic syndrome associated with T1D and is susceptible to MERS-CoV infection to determine the contribution 
of hyperglycemia in the absence of obesity. This lean, hyperglycemic model can also be used to study the effects 
of hyperglycemia alone for other respiratory infections, including influenza virus and bacterial pathogens.
Sex-specific differences in the development of  obesity and metabolic disease also exist in both humans 
and mice. Male C57BL/6 mice are more susceptible than females to diet-induced obesity and the sub-
sequent development of  metabolic disease (40, 54). Similarly, we found that HFD DPP4H/M male mice 
exhibited more severe diabetes compared with HFD female mice (Figure 1). Several factors are thought 
to contribute to sexual dimorphic development of  obesity-related metabolic disease, including sex-specif-
ic differences of  immune cell development and function, adipose-related immune activation, adipocyte 
proliferation and development, and the contribution of  sex steroids to adipocytes (54, 55). For these rea-
sons, the majority of  studies investigating the effects of  obesity or T2D on the pathogenesis of  infectious 
diseases use male mice. We chose to compare HFD-induced diabetic male and HFD female mice to 
better understand how the severity of  diabetes affects pathogenesis. We found that diabetic male mice 
experienced more severe disease following MERS-CoV, and this was characterized by a prominent delay 
of  cellular infiltration and prolonged lung pathology, alterations in CD4+ T cell and IMM pulmonary 
infiltration, and dysregulated cytokine and chemokine responses. Although the HFD female DPP4H/M 
mice did develop mild metabolic syndrome, this had little effect on the clinical course of  disease and lung 
pathology, a minor delay in cellular infiltration, and had minimal effects on cytokine and chemokine 
expression and immune cell infiltration in the lung. These data demonstrate that the severity of  diabetes 
or poor glycemic control leads to more severe MERS-CoV–induced disease. This suggests that patients 
with diabetes who are being effectively treated for diabetes may not have as high of  a risk of  severe MERS 
disease as those with uncontrolled glucose levels.
Increased infection with viral and bacterial pathogens has been characterized in diabetic humans and 
animal models. Infection of  M. tuberculosis and B. pseudomallei has been previously shown to lead to reduced 
ability to control bacterial replication, leading to systemic dissemination in diabetics (30). We did not 
observe any differences in MERS-CoV replication or clearance in the lungs in diabetic mice. Furthermore, 
we did not observe any differences in the levels of  genomic viral RNA or viral mRNA in extrapulmonary 
tissues of  diabetic or HFD mice. These data suggest that increased systemic spread of  MERS-CoV is not a 
cause of  increased disease severity as is observed with bacterial respiratory pathogens.
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Immune dysfunction in the context of  diabetes alone or following infection has been reported for a 
wide variety of  immune cells, not just monocytes, macrophages, and CD4+ T cells (30). Although differ-
ences in recruitment to the lung following MERS-CoV infection was not noted for neutrophils, NK cells, 
or CD8+ T cells, determining the functionality of  these cells along with characterizing the DC, NK T cell, 
and γδ cell response is important in furthering our understanding of  how diabetes affects MERS-CoV 
pathogenesis. CD8+ T cells are of  particular interest because we have previously shown that CD8+ T cells 
play a deleterious role during MERS-CoV infection in our human DPP4 (hDPP4) mouse model (35). In 
humans, antigen-specific CD8+ T cells were found in patients with acute MERS-CoV infection (56) and 
correlated with disease severity (57). Although the number of  CD8+ T cells found in the lung in response 
to MERS-CoV infection was not altered in diabetic mice, the cytotoxic function of  these cells may be. In 
diabetic humans infected with M. tuberculosis, CD8+ T cell numbers in circulation were similar to healthy 
patients, but a higher frequency of  these cells produced IFN, IL-2, and IL-17F along with having decreased 
antigen-specific expression of  cytotoxic markers (58).
If  and how CD4+ T cells contribute to MERS-CoV pathogenesis is not clear, but we found alterations 
in the CD4+ T cell response to MERS-CoV infection in diabetic mice although to a lesser extent than we 
found differences in the IMM response. The magnitude of  infiltrating CD4+ T cells was reduced during the 
first 7 days following MERS-CoV infection in diabetic mice, which correlated with lower levels of  Cxcl10 
expression in the lung. In addition to dampened cellular recruitment, the decrease in CD4+ T cells could 
also be due to a reduction in the proliferative capacity of  T cells, which has been observed previously under 
hyperglycemic conditions (59). Analysis of  human sera from patients with MERS showed serum cytokine 
profiles indicative of  Th1 and Th17 responses (60). Similarly, we saw the upregulation of  Ifng and Il17a, 
but not Il4, in the lungs of  MERS-CoV–infected mice, and diabetic mice had higher upregulation of  Il17a. 
This suggests that, in addition to a decrease in the number of  CD4+ T cells in the lungs of  diabetic mice, 
the functional profile of  the CD4+ T cell compartment may be altered. The effects of  increased IL-17 or an 
increase in the Th17 cell response to MERS-CoV infection is not known. However, during other respiratory 
viral infections, such as influenza, increased Th17 responses can be pathogenic or protective, depending on 
the context (61, 62). Diabetes results in a proinflammatory homeostatic immune response skewed toward 
Th1 and Th17 CD4+ T cells and a decrease in Tregs (30). Similarly, in diabetic humans infected with M. 
tuberculosis, an increase in antigen-specific Th1 cells and both non–antigen-specific and antigen-specific 
Th17 cells as well as increased serum levels of  Th1 and Th17 cytokines were observed (63). Increased IL-17 
expression in diabetic mice may also be coming from other cellular sources, including CD8+ T cells, γδ T 
cells, NK T cells, innate lymphoid–like type 3 cells, and neutrophils (59, 64). Interestingly, higher levels of  
Foxp3 expression were observed 21 days after infection in diabetic mice following MERS-CoV infection. 
This suggests that the immunoregulatory T cell response following MERS-CoV infection is affected by 
diabetes. Future studies are focused on determining the functional differences of  CD4+ T cells and their 
importance in diabetic mice following MERS-CoV infection.
Macrophage infiltrates are found in the lungs of  MERS-CoV–infected patients (10, 11). We have pre-
viously shown that macrophages were protective during MERS-CoV infection in our animal model (35). 
However, in a different animal model for MERS-CoV that requires a mouse-adapted MERS-CoV strain, 
an increase in the IMM response and a decrease in the NK, T, and B cell response during the more viru-
lent infection suggests a pathogenic role for these cells (36). We found that diabetic mice had fewer IMMs 
in the lungs 7 days after MERS-CoV infection, and this correlated with lower levels of  Ccl2 expression. 
Macrophage skewing affects how the lung resolves infection and tissue damage. In diabetics, macrophage 
function is altered, with a switch from predominately M2 macrophages at homeostasis to proinflammatory 
M1 macrophages (30). We found reduced expression of  the M1 macrophage–associated cytokines Tnfa, 
Il6, and Il12b in the lungs of  diabetic mice infected with MERS-CoV. This response is similar to what is 
observed after bacterial infection in which macrophages from diabetic mice or humans have been shown 
to have reduced phagocytic function and expression of  TNF-α, IL-6, CCL2, and IL-12 (65–67). As proin-
flammatory gene expression was beginning to decline around 7 to 10 days after MERS-CoV infection, 
control mice upregulated the M2 marker Arg1, suggesting a switch to a more regulatory macrophage phe-
notype, which is important for resolving inflammation and promoting wound healing. Diabetic mice did 
not upregulate Arg1 as efficiently as control mice, suggesting a defect in initiating this regulatory response. 
Improper initiation of  a regulatory macrophage response may contribute to the prolonged lung pathology 
and inflammation observed in diabetic mice. Although only infiltrating IMMs were analyzed in this study, 
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delineating the effect that diabetes has on the functionality of  infiltrating IMMs as well as resident alveolar 
macrophages and how these cell subsets affect disease outcome will be important in better understanding 
how diabetes leads to worse disease following MERS-CoV infection.
We have developed a small animal model that recapitulates the human epidemiological observation that 
patients with comorbid diabetes have more severe disease from MERS-CoV infection and have shown that 
more severe, prolonged disease is associated with a dysregulated immune response upon infection. Many 
of  the immune characteristics that we observed in diabetic mice following MERS-CoV infection have also 
been identified in diabetics following respiratory bacterial infections, suggesting that there may be a common 
mechanism of dysfunction in the respiratory tract of  diabetics, which has broader implications for therapeutic 
development. Human MERS patients with comorbid diabetes also show evidence of  increased lethality. Cur-
rently, this model does not recapitulate this feature, but future studies will be performed to increase lethality by 
increasing the dose of  the virus used or by using the mouse-adapted MERS-CoV strains previously developed 
(37, 68). Our current model to study diabetes and MERS-CoV infection provides the opportunity to investi-
gate a wide variety of  questions, such as the contribution of  age to disease severity in diabetic mice, how anti-
T2D drugs affect pathogenesis and disease outcome, and the efficacy of  current therapeutics and vaccines in 
the context of  diabetes. This model is a stepping-stone in understanding how diabetes affects MERS-CoV 
pathogenesis and how to effectively develop therapeutics and vaccines for this high-need population.
Methods
Virus and cells. The MERS-CoV Jordan strain (GenBank accession KC776174.1, MERS-CoV-Hu/Jor-
dan-N2/2012) was used for these studies. MERS-CoV Jordan was propagated on Vero E6 cells maintained 
in Minimum Essential Medium (Corning) supplemented with 10% v/v fetal bovine serum (FBS; Milli-
poreSigma), 1% v/v l-glutamine (Gibco, Thermo Fisher Scientific), and 1% v/v penicillin-streptomycin 
(Gemini Bioproducts) at 37°C in 5% CO2. Medium was collected 3 days after infection and centrifuged to 
remove cellular debris. The resulting inoculum was titered using a plaque assay on Vero E6 cells.
All experiments with live MERS-CoV were performed under biosafety level 3 conditions at the Univer-
sity of  Maryland School of  Medicine.
Induction of  diabetes in mice. hDPP4-expressing C57BL/6 mice as described previously (34) were used 
in these experiments. hDPP4-heterozygote (DPP4H/M) mice were bred and maintained at the University of  
Maryland School of  Medicine by crossing hDPP4-homozygote (DPP4H/H) mice with wild-type C57BL/6 
mice (DPP4M/M). At 4 to 6 weeks of  age, hDPP4 mice were put on a diet of  normal chow (22% kcal from 
fat; Teklad, 2019S) or a diet consisting of  high-fat chow (60% kcal from fat; Teklad, TD.06414) and main-
tained on this diet for 12 to 17 weeks. After 12 to 17 weeks, mice were weighed and tested for elevated blood 
glucose levels and glucose intolerance.
To evaluate glucose intolerance, we used the IPGTT. Normal-chow and high-fat–chow mice were fast-
ed overnight (~16 hours) and weighed, and baseline fasted glucose levels were measured using Contour 
glucose test strips and glucose meter (Bayer). A 20% w/v solution of  glucose was prepared fresh in PBS 
and administered via intraperitoneal injection at a final concentration of  2 g/kg. Blood glucose levels were 
monitored at 30, 60, 90, and 120 minutes after glucose administration. The resulting values were normal-
ized to the baseline glucose levels and the AUC was determined.
Insulin ELISA. Mice were fasted for 16 hours, blood was collected via a retroorbital bleed, and serum 
was isolated. To determine the serum insulin concentration, we used the Insulin ELISA Kit (Crystal Chem 
90080) and performed the assay according to the manufacturer’s protocol.
Mouse infections. All experiments used male and female DPP4H/M mice maintained on either normal 
chow or high-fat chow for 12–17 weeks (16–22 weeks of  age). Mice were infected approximately 1–2 weeks 
following diabetes testing, allowing adequate time to recover from the fasting and IPGTT. Before infection, 
mice were transferred to the animal biosafety level 3 facility at the University of  Maryland School of  Med-
icine and allowed to acclimate for at least 3 days. Mice were anesthetized by intraperitoneal injection using 
50–150 μL of  a mix of  xylazine and ketamine diluted in PBS. Once anesthetized, mice were intranasally 
inoculated with 50 μL of  PBS, 1.5 × 104 PFU, or 1.5 × 105 PFU of  MERS-CoV Jordan diluted in PBS for 
a total inoculation volume of  50 μL. Mice were weighed and monitored daily for clinical score. Mice were 
scored using the following scale: 0 = healthy; 1 = slight ruffling of  the fur, altered hind limb posture; 2 = 
mildly labored breathing, no lethargy, 3 = moderately labored breathing, lethargy; 4 = severely labored 
breathing, severe lethargy; and 5 = dead. Mice that lost more than 70% of  their starting body weight were 
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euthanized using isoflurane (Butler Animal Health Supply). Only mice found dead in the cage were scored 
a 5; mice euthanized for reaching the weight loss criterion were scored as last observed.
Tissue collection was performed on infected mice at days 2, 4, 7, 10, 14, and 21 after infection. Mice 
were euthanized using isoflurane and lungs were collected and homogenized in Trizol for RNA extraction 
or PBS for virus quantification and stored at –80°C. Other lung sections were fixed and stored in 10% neu-
tral buffered formalin for histological evaluation.
MERS-CoV quantification. To determine infectious MERS-CoV titers, lungs from infected mice were 
homogenized in 1 mL of PBS (Quality Biologicals, Inc.) using 1-mm glass beads (MilliporeSigma) and a 
beadruptor (Omni International, Inc.). MERS-CoV titers in PFU per milliliter were determined by plaque 
assay on Vero E6 cells and converted to PFU per gram of lung based on the mass of  the harvested lung tissue.
For MERS-CoV genomic RNA and mRNA quantification was performed as previously described (35). 
Briefly, lung tissue was harvested and homogenized in TRIzol (Ambion). RNA was extracted per the man-
ufacturer’s instructions using the Direct-zol RNA Miniprep Kit (Zymo Research). Fast 1-step PCR mix 
(Life Technologies) was used along with primer and probe sets targeting UpE for viral genomic RNA, the 
leader sequence and M for viral mRNA, and the mouse TfRC, which was used as the endogenous control. 
Relative expression levels of  genomic MERS-CoV viral RNA and mRNA were determined by (TfRCCt/
GeneCt)Infected/(TfRCCt/GeneCt)PBS, which means a relative expression value of  1 is uninfected.
Gene expression. Lung tissue was homogenized in 1 mL of  TRIzol (Ambion) using 1-mm glass beads 
(MilliporeSigma) and a beadruptor (Omni International, Inc.). RNA was extracted using the DIRECT-
zol Mini RNA Extraction kit (Zymo Research) per the manufacturer’s instructions. RNA (0.5 μg) was 
transcribed into cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). 
Gene expression was performed using 1 μL of  input cDNA using the PowerUp SYBR Green Master Mix 
(Applied Biosystems) and PrimeTime qPCR Primer Assays (Integrated DNA Technologies) targeting 
mouse Arg1 (Mm.PT.58.8651372), Ccl2 (Mm.PT.58.42151692), Cxcl10 (Mm.PT.58.28790444), Foxp3 (Mm.
PT.58.8579739), Ifng (Mm.PT.58.41769240), Il10 (Mm.PT.58.13531087), Il12b (Mm.PT.58.12409997), Il17a 
(Mm.PT.58.6531092), Il4 (Mm.PT.58.32703659), Il6 (Mm.PT.58.10005566), Nos2 (Mm.PT.58.43705194), 
Tnfa (Mm.PT.58.12575861), and Gapdh (Mm.PT.39a.1). Gene expression was calculated using the ΔΔCt 
method with Gapdh as the endogenous control and fold change calculated relative to mock infected lungs 
of  mice of  the same sex and diet.
Flow cytometry. Uninfected or MERS-CoV–infected mice were euthanized with isoflurane. Mice 
were perfused using 10 mL of  cold PBS, and lungs were excised and placed in cold PBS. Single cells 
were isolated from lungs using the gentleMACS system (Miltenyi Biotec). Lungs were placed in C tubes 
(Miltenyi Biotec) containing RPMI medium with 5% v/v FBS, 1 mg/mL of  collagenase D (Roche), 
and 0.1 mg/mL of  DNAse I (Roche). Lungs were run on m_lung_01 and allowed to digest for 30 min-
utes at 37°C with intermittent shaking followed by running m_lung_02. Cell suspensions were filtered 
on a 70-μm filter (BD), and cells were pelleted by centrifugation. Red blood cells were lysed in ammo-
nium-chloride-potassium lysis buffer (Quality Biological, Inc.) and subsequently washed with RPMI 
containing 5% w/v FBS. Total live cells were counted using trypan blue exclusion.
Approximately 1 × 106 cells were plated and washed twice with PBS containing 2 mM EDTA. Cells 
were stained for viability using the Live/Dead Fixable Aqua Dead Cell Stain Kit (Molecular Probes). Cells 
were washed with PBS containing 2 mM EDTA and resuspended in blocking buffer consisting of  Mouse Fc 
Block (BD) and PBS containing 0.5% BSA and 2 mM EDTA. After blocking, cells were stained with anti-
body cocktails made in PBS containing 0.5% BSA and 2 mM EDTA. The antibodies used were as follows: 
CD45 Alexa Fluor 700 (BioLegend clone 30-F11), CD11b PerCP-Cy5.5 (BioLegend clone M1/70), Ly6G 
PECy7 (BD clone 1A8), Ly6C eFluor450 (eBioscience clone HK1.4), CD3 APC-eFluor780 (eBioscience 
clone 145-2C11), CD4 FITC (BioLegend clone GK1.5), CD8a APC (BioLegend clone 53-6.7), CD19 PE 
(BD clone 6D5), and NK1.1 PerCP-Cy5.5 (BD clone PK136). Stained cells were washed twice and fixed 
for 1 hour in FluoroFix (BioLegend). Fixed cells were washed once in PBS containing 0.5% BSA and resus-
pended in PBS containing 0.5% BSA and 2 mM EDTA. Samples were acquired (approximately 500,000 
events) using the LSR II flow cytometer (Beckton Dickinson), and data were analyzed using FlowJo analysis 
software (FlowJo, LLC).
Histology. Formalin-fixed lungs were embedded in paraffin, and 5-μm sections were cut followed by 
staining with hematoxylin and eosin by the Pathology Electron Microscopy and Histology Laboratory at 
the University of  Maryland School of  Medicine. Slides were blinded and were scored by a board-certified 
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veterinary pathologist for the presence of  pathological characteristics of  disease, including perivascular 
inflammation, bronchiolar inflammation, eosinophils, neutrophils, lymphocytes, macrophages, edema, 
hemorrhage, pleuritis, and necrosis. The scoring scale used was as follows: 0 = no inflammation; 1 = scant 
inflammation (<5% multifocal or 1 small focus); 2 = mild inflammation, <25% parenchyma; 3 = moderate 
inflammation, 25%–50% parenchyma; 4 = marked inflammation, 50%–75% parenchyma; and 5 = severe 
inflammation, >75% parenchyma.
Statistics. All statistical analysis was performed with GraphPad Prism. Metabolic parameters of  HFD-
fed DPP4H/M mice were analyzed using a 1-way ANOVA with Tukey’s posttest. A 2-way ANOVA with 
Holm-Šídák posttest was used to analyze the IPGTT time course as well as weight loss, clinical signs of  
disease, virus titers, infiltration of  immune cells, and cytokine and chemokine expression during infection. 
Unpaired 2-tailed t test with Holm-Šídák correction for multiple comparisons was used to analyze viral 
genomic RNA and mRNA levels in various tissues 7 days after infection. All statistical analyses were done 
on non–log-transformed data. Statistical significance was defined as P < 0.05.
Study approval. All mouse experiments were performed at the University of  Maryland School of  Med-
icine in accordance with protocols approved by the Institutional Animal Care and Use Committee under 
protocols 0115009 and 1217008 and the U.S. Animal Welfare Act.
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